Study of Poziotinib in Japanese Patients With NSCLC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
A Phase 1/2, open-label, multicenter study to determine dose, tolerability, safety and efficacy of poziotinib in Japanese patients non-small cell lung cancer (NSCLC).
Epistemonikos ID: 82c030246ba452d687b808de65a8d266b5444f43
First added on: May 07, 2024